Parkinson's Disease Psychosis
9
2
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
78%
7 trials in Phase 3/4
83%
5 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Comparing Antipsychotic Medications in LBD Over Time
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Expanded Access of Pimavanserin for Patients With PD Psychosis
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis